2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1054

Healthcare Utilization Profiles in Rheumatoid Arthritis – a Cluster Analysis
Abstract Number: 2206

Healthy Weight Loss Is Associated with Improved Pain and Function over 8 Years in Overweight Subjects with Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 985

Heart Failure Hospitalizations Among SLE and Diabetes Mellitus Patients Compared to the General U.S. Medicaid Population
Abstract Number: 1049

Heart Rate Variability Testing with Autonomic Nervous System Optimization: Could It Change the Course of Spending for Rheumatoid Arthritis Patients in the U.S.? an Exploratory Minimal Model Analysis
Abstract Number: 2381

Hematologic Abnormalities during the Use of Low Dose Methotrexate for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 2619

Hemophagocytic Syndrome in Patients from SLE Registry from the Spanish Society of Rheumatology (RELESSER)
Abstract Number: 369

Hepatitis A Virus Vaccination in Juvenile-Onset Systemic Lupus Erythematosus
Abstract Number: 1099

Hepatitis B Reactivation in Rheumatologic Patients
Abstract Number: 1976

High and Low Widespread Pain Index Fibromyalgia Patient Groups, Same, or Different?
Abstract Number: 1074

High Cholesterol Levels By ApoE Defenciency Reduce Bone Destruction in Murine Antigen-Induced Arthritis Via Inhibition of Osteoclastogenesis
Abstract Number: 2908

High Disease Activity Is a Predictor of Depression and Persistent Depression in Early Rheumatoid Arthritis: Results from a Rheumatoid Arthritis Cohort
Abstract Number: 913

High Erythrocyte Levels of the n-6 Polyunsaturated Fatty Acid Linoleic Acid Are Associated with Lower Risk of Subsequent Rheumatoid Arthritis in a Southern European Nested Case-Control Study
Abstract Number: 1638

High Genetic Risk Score Is Associated with Increased Organ Damage in SLE
Abstract Number: 2385

High Incidence of Hepatitis Related to HBV Reactivation in Rheumatoid Arthritis Patients with Resolved Hepatitis B Infection during Rituximab Treatment
Abstract Number: 2347

High Interferon (IFN) Signatures and Overlapping Clinical Features Characterize Subgroups of Patients with Presumed IFN-Mediated Autoinflammatory Diseases

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].